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Abstract
Background: Effective digestive enzymes are crucial for successful islet isolation. Supplemental proteases are essential
because they synergize with collagenase for effective pancreatic digestion. The activity of these enzymes is critically
dependent on the presence of Ca2þ ions at a concentration of 5–10 mM. The present study aimed to determine the Ca2þ
concentration during human islet isolation and to ascertain whether the addition of supplementary Ca2þ is required to
maintain an optimal Ca2þ concentration during the various phases of the islet isolation process. Methods: Human islets
were isolated according to standard methods and isolation parameters. Islet quality control and the number of isolations
fulfilling standard transplantation criteria were evaluated. Ca2þ was determined by using standard clinical chemistry routines.
Islet isolation was performed with or without addition of supplementary Ca2þ to reach a Ca2þ of 5 mM. Results: Ca2þ
concentration was markedly reduced in bicarbonate-based buffers, especially if additional bicarbonate was used to adjust the
pH as recommended by the Clinical Islet Transplantation Consortium. A major reduction in Ca2þ concentration was also
observed during pancreatic enzyme perfusion, digestion, and harvest. Additional Ca2þ supplementation of media used for
dissolving the enzymes and during digestion, perfusion, and harvest was necessary in order to obtain the concentration
recommended for optimal enzyme activity and efficient liberation of a large number of islets from the human pancreas.
Conclusions: Ca2þ is to a large extent consumed during clinical islet isolation, and in the absence of supplementation, the
concentration fell below that recommended for optimal enzyme activity. Ca2þ supplementation of the media used during
human pancreas digestion is necessary to maintain the concentration recommended for optimal enzyme activity. Addition of
Ca2þ to the enzyme blend has been implemented in the standard isolation protocols in the Nordic Network for Clinical Islet
Transplantation.
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Introduction
Clinical islet transplantation constitutes an efficient treat-
ment option for subjects with severe type 1 diabetes compli-
cated by a lack of hypoglycemia awareness. Compared with
whole-pancreas transplantation, islet transplantation has a
low frequency of serious complications1; an outstanding
problem, however, is inconsistency in the ability of particu-
lar enzyme blends to catalyze efficient digestion of the pan-
creas, allowing liberation of a large number of islets with
intact function. This problem has stimulated huge efforts
toward characterizing and standardizing enzymes for islet
isolation, and currently several manufacturers provide
GMP-grade (Good Manufacturing Practice) products. Even
so, each islet isolation center experiences not only lot-to-lot
variation in digestion effectiveness but also a significant
variability between individual pancreata. Surprisingly, an
enzyme deemed insufficient in one islet isolation facility can
work properly when evaluated in another center. These
experiences point to a thus-far unrecognized critical compo-
nent governing enzyme efficiency during clinical islet isola-
tion that cannot be detected by standard assays of enzyme
activity. For decades, Ca2þ has been known to be essential
for the enzymatic activity of collagenase, neutral protease,
thermolysin, and clostripain2–5, and all manufacturers who
make these enzymes available add Ca2þ to their enzymes.
However, the total amount of Ca2þ provided is not sufficient
when preparations are further diluted to 200–400 ml, as is
usually done for clinical islet isolation. Therefore, the
Clinical Islet Transplantation (CIT) protocol stipulates Ca2þ
supplementation of the digestion solution with a target con-
centration of 5 mM for collagenase from two manufacturers
(Roche and Serva)6.
The aim of the present paper was to examine the actual
Ca2þ concentrations in the medium during the various
phases of clinical islet isolation and to determine whether
the further addition of Ca2þ is required during the islet iso-
lation process to obtain the recommended concentration.
Materials and Methods
Organ Procurement
All participating centers within the Nordic Network for
Clinical Islet Transplantation (NNCIT; http://nordicislets.
medscinet.com) used standard organ procurement proce-
dures7. Centers within the NNCIT include the University
Hospital, Gothenburg; University Hospital, Malmö;
Karolinska Institute, Stockholm; Uppsala University
Hospital, Uppsala; the Surgical Hospital, Helsinki Univer-
sity, Helsinki; Oslo University Hospital, Rikshospitalet,
Oslo; and Rigshospitalet, Copenhagen.
Donor, Transport, Islet Isolation, and Islet Maintenance
Donors were selected by applying the same criteria as for
clinical kidney donation in the Scandiatransplant region, but
pancreata were only retrieved from donors of 25–70 years of
age. Exclusion criteria included a glycosylated hemoglobin
A1c (HbA1c) >48 mmol/mol according to the International
Federation of Clinical Chemistry and Laboratory Medicine8.
Statistical analysis of the donor characteristics and para-
meters of the islet isolation was performed using a nonpara-
metric test.
Details for islet isolation were described previously9,10.
All standard operating procedures are available at http://nor
dicislets.medscinet.com. A selected enzyme blend consist-
ing of collagenase, thermolysin (both Roche, Indianapolis,
IN, USA), and clostripain (Vitacyte, Indianapolis, IN, USA)
was utilized.
Samples taken from the dissolved enzyme blend during
the recirculation and harvest phases were analyzed on an
Abbott Architect c16000 platform (Department of Clinical
Chemistry, Uppsala University Hospital, Uppsala, Swe-
den)11. The [Ca2þ] in all solutions used during the isolation
process was analyzed directly after preparation and at vari-
ous time-points during the islet isolation process, as indi-
cated in Figure 1.
In total, 19 isolations were performed between January
and November 2017. The isolations in the control group
(n ¼ 9) were performed according to the NNCIT’s standard
procedure. In the group with supplementary Ca2þ, one iso-
lation was performed following the protocol of the National
Institutes of Health Clinical Islet Transplantation Consor-
tium (CIT) using 10 mM of Ca2þ in HBSS for dissolving
the enzymes (see Table 1), followed by ordinary CMRL
culture medium in the recirculation and harvest phases of
the isolation. Since the CIT protocol is not our standard
protocol and we were only interested in [Ca2þ] during the
isolation process, we have not included this isolation in
the evaluation.
The subsequent nine isolations that included Ca2þ sup-
plementation were performed using Ringer’s acetate-based
solutions according to the NNCIT’s standard procedure. Ini-
tially the [Ca2þ] was adjusted to 5 mM only in the stock
solution used for dissolving the enzymes (Table 1). A second
isolation was performed by increasing the [Ca2þ] to 5 mM in
the stock solution as well as during the harvest phase. During
a third isolation, both the stock solution and the recirculation
solution had a [Ca2þ] of 5 mM, and the [Ca2þ] in the
medium for harvest was 4 mM. The lessons learned from
these first isolations were implemented to yield a [Ca2þ] of
5–7 mM during the entire islet isolation process performed
on an additional six consecutive pancreata.
Islet Quality Control
All functional and viability analyses were performed accord-
ing to standard protocols (http://nordicislets.medscinet.com/
en.aspx). The day after islet isolation, quality analyses were
performed using a dynamic glucose-stimulated insulin secre-
tion (GSIS) perfusion test (Brandel, London, UK) (Figure 2)
on 20 handpicked islets to calculate the stimulation index
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(average of the high-glucose phase divided by the average of
the low-glucose phase)12. Islet quality control in one isola-
tion was performed using a modified protocol that mainly
included a shortened perfusion period. All insulin values
were measured using a human insulin-specific ELISA
(Mercordia, Uppsala, Sweden).
CUSUM Test
The cumulative sum chart test (CUSUM) is a sequential
analysis technique used for monitoring change in relation
to a set number – for example, the mean number of islet
equivalents (IEQ) isolated per pancreas. For each isolation,
the difference in IEQ, negative or positive, in relation to the
mean is calculated. Whenever there is a systematic increase
or decrease in the number of IEQ obtained, a deviation of the
curve from the mean occurs.
Results
Donor Characteristics
The donor characteristics for the islet isolations involving
supplementary Ca2þ (n ¼ 9) and a control group (n ¼ 9)
following the NNCIT protocol were not significantly differ-
ent regarding donor age, gender, body mass index (BMI),
HbA1c, cold ischemia time, dissection time, trimmed pan-
creas weight, digestion and harvest time, pellet volume
before separation, and amount of pancreas left in the cham-
ber. Neither were the parameters for the donor from the one
isolation following the CIT protocol.
Ca2þ Concentration During the Islet Isolation Process
HBSS is used as the basic fluid during the isolation process
in the CIT network, while Ringer’s acetate is used in the
Nordic network, but both contain 2 mM Ca2þ without addi-
tives. When we followed the CIT protocol for supplementa-
tion of Ca2þ, [Ca2þ] levels reached the expected 10 mM
level in the stock solution but had already dropped dramati-
cally during the recirculation phase (Figure 1).
Similarly, the addition of Ca2þ increased the [Ca2þ] to 5
mM in Ringer’s acetate. Adding Ca2þ only to the stock
solution raised the [Ca2þ] to 5 mM, but it dropped to 2
mM during the recirculation phase and to <1 mM during the
collection phase. When we added additional Ca2þ to the
Figure 1. Calcium levels measured during the islet isolation process. The dotted line indicates a calcium level of 5 mmol/L.
Table 1. Addition of Supplementary Calcium to Media to Achieve
the Target Concentrations Indicated.





5 mM 5 mM 5 mM 5 mM 7 mM 10 mM
Recirculation – 5 mM – 5 mM 7 mM –
Harvest – 4 mM 4 mM 5 mM 7 mM –
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stock solution and to the fluids used during the collection
phase, the expected rise in [Ca2þ] to 5 mM was confirmed,
followed by a continuous drop to <3 mM during the recircu-
lation and digestion phases and a slight increase again when
we used Ringer’s acetate supplemented with Ca2þ to target a
concentration of 5 mM. When we adjusted the [Ca2þ] levels
to 5 mM in the stock solution and recirculation phase and
also to 4 mM during the collection phase, we saw only a
minor dip during the recirculation phase, and the levels
remained stable during the collection phase. The [Ca2þ] was
*5 mM during all three phases when the level was adjusted
to 5–7 mM in all solutions (Figure 1).
Isolation Results
The results of the isolations in the supplementary Ca2þ
group and the control group were significantly different only
for the number of IEQ, which was significantly higher
(P < 0.05) for the supplementary Ca2þ group: 323,730 (range
202,500–453,739) vs. 147,319 (range 55,978–266,086);
there was no significant difference (P > 0.05) between the
groups regarding the purified tissue volume, IEQ/g pancreas,
total purity, and recovery after 1 day of storage (Table 2).
Islet size distribution was comparable to that previously
published (Figure 3)13.
The quality assessment of the islets revealed no negative
impact of the additional Ca2þ during the various periods on
the SI values (3.0 [range 1.3–5.5]) or levels of insulin
release. The GSIS perfusion curves showed stimulated
insulin release, with an initial spike followed by continued
and sustained insulin release until a return to low glucose
levels. Data are shown only for the isolations with supple-
mentary Ca2þ during the entire isolation process (Figure 2).
The cumulative plot of the IEQ for islet isolation accord-
ing to the NNCIT protocol showed an increasing number of
cumulative IEQ when additional Ca2þ was used to obtain a
[Ca2þ] of 5–7 mM in all media, when compared to a series of
consecutive isolations using the standard procedure with
extra Ca2þ supplementation only in the stock solution used
for dissolving the enzyme blend (Figure 4).
Discussion
The results presented here indicate that the concentration of
free Ca2þ during the islet isolation procedure, conducted
according to the present CIT recommendations and other
standardized protocols for clinical islet isolation, often can
be below 1 mM even under conditions in which supplemen-
tary Ca2þ has been added to achieve an initial target concen-
tration of 5 mM. It is well known that when Ca2þ is added to
bicarbonate-buffered solutions, precipitation of calcium car-
bonate will occur, thereby reducing the amount of free Ca2þ;
however, this reaction has thus far been overlooked in the
field of clinical islet isolation.
Calcium carbonate (CaCO3) is a common substance that
occurs in rock in the form of the minerals calcite and arago-
nite (found, for example, in limestone). It is the main com-























Supplementary Ca2+ 5 mM+5 mM+5 mM (n = 4) Control (n = 9)
Figure 2. Insulin release curve in response to dynamic glucose perfusion. Islets were perfused with high glucose (16.7 mM) from 42 to 84
min, whereas other fractions were exposed to low glucose (1.67 mM). Data shown from the final series of isolations using supplementary
Ca2þ of 5 mM in all solutions.
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and eggs. Calcium carbonate is created when calcium ions
react with carbonate ions. Once formed, calcium carbonate is
an insoluble precipitate that will not dissolve even if diluted
in large volumes of fluid. Based on the results presented
here, the use of bicarbonate-buffered solutions such as HBSS
and of bicarbonate for pH adjustment, both recommended by
the CIT, should be avoided. Several other buffer systems can
be used to avoid the formation of calcium carbonate, such as
a HEPES-based buffer, together with pH adjustment using
sodium hydroxide.
More surprising was our finding of a significant con-
sumption of Ca2þ during the islet isolation procedure. The
mechanism(s) through which Ca2þ is consumed is/are cur-
rently unknown. However, during digestion, Ca2þ is exposed
to the extracellular matrix (ECM) of the pancreas. The
ECM is composed of various highly negatively charged
Table 2. Characteristics of Donors and Donor Pancreata.
Supplementary Ca2þ (n ¼ 9) Control (n ¼ 9)
Mean Range Mean Range P value (P < 0.05)
Donor age 55 years 34–69 61 years 54–70 0.477 ns
Gender (male/female) 6/3 NA 4/5 NA NA
BMI 28.2 23.9–33.1 25.5 21.6–30.5 0.7414 ns
HbA1c 37.7 31.0–47.0 38.2 34–41 0.28914 ns
Cold ischemia time 09:59 h 04:41–16:55 h 10:22 h 03:48–21:28 h 0.85716 ns
Dissection time 0:54 h 0:38–1:14 h 0:52 h 0:44–1:11 h 0.92828 ns
Trimmed pancreas 140 g 80–292 g 93 g 41–144 g 0.151 ns
Digestion time 16 min 8–24 min 24 min 16–57 min 0.6432 ns
Harvest time 0:37 h 0:27–0:52 h 00:45 h 00:31–1:11 h 0.18684 ns
Pellet volume before separation 45 ml 20–85 ml 33 ml 10–51 ml 0.7672 ns
Pancreas left in the chamber 22 g 5–61 g 19 g 7–50 g 0.89656 ns
Extent of pancreas digestion (%) 85.3 57.6–96.2 80.8 66.2–93.1 0.4009 ns
IEQ 323,730 202,500–453,739 147,319 55,978–266,086 0.0027 P < 0.05
Purified tissue volume (ml) 2196 710–5990 1125 350–1,525 0.05744 ns
Total purity (%) 44 14 -71 37.7 12–62 0.45326 ns
IEQ/g pancreas 2852 1867–3,969 2296 749–5,676 0.13362 ns
Recovery after 1 day (%) 109 82–136 106 58–145 0.05118 ns
BMI, body mass index; IEQ, islets equivalent.
Figure 3. Islet size distribution as a percentage of total IEQ number. Data from one isolation following the CIT protocol are not included.
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macromolecules14, such as laminins, collagens, aggrecan,
heparan sulfate/heparan sulfate proteoglycans, and hyaluro-
nan, which are liberated in large amounts during digestion
and can potentially bind large quantities of Ca2þ15.
Irrespective of the cause, we found that the [Ca2þ]
during isolation fell to concentrations that are known to
negatively affect enzyme activity2–5. To counteract this
loss of free Ca2þ, the media used during enzyme perfu-
sion of the pancreas, digestion, and harvest must be sup-
plemented with Ca2þ.
A validated digital image analysis technique was used in
the present study to avoid bias, investigator variations, and
overestimation of the islet number and purity16,17. The qual-
ity of the islets was good, with no observable negative
effects of the procedure on the islet number, purity of the
islets, size distribution, or islet recovery after culture. Simi-
larly, the dynamic GSIS showed well-preserved islet func-
tion, and all islet preparations were considered acceptable
for clinical use.
Supplementation with Ca2þ seems to improve the effi-
cacy of the enzyme blend without causing any negative
effect on islet number, purity, or function. The rate of clin-
ical islet transplantations is envisioned to increase substan-
tially if a Ca2þ concentration optimal for enzyme activity is
applied. From a health care and insurance perspective, the
increased rate of transplantation itself should translate to a
substantial improvement in the cost–benefit of islet
transplantation18. Furthermore, potentiation of the enzyme
blend by Ca2þ supplementation may allow the use of lower
quantities of enzymes during human islet isolation, further
reducing the cost of clinical islet isolation.
The relative importance of Ca2þ in the digestion of a
specific pancreas may vary between donors – that is, diges-
tion of the pancreas from some donors may be almost com-
plete without supplementation with Ca2þ, whereas in other
cases the addition of Ca2þ may be essential for efficient
digestion. The currently used enzyme blend was of good
efficiency, but as usually observed, there was variation in
the digestion efficiency between donors. Notably, this blend
of enzymes showed almost no digestion of a pancreas
retrieved from one optimal organ donor. Macroscopically,
the pancreas was without surrounding fat, and examination
after dividing the pancreas into pieces before digestion
demonstrated an organ without fibrosis or infiltrating fat.
The center in Uppsala currently has experience with more
than 2300 human pancreata, and this pancreas was deemed
to be among the top 20 from a quality perspective. However,
after digestion for 25 min, the islet isolation was stopped
because no material was released from the Ricordi chamber.
Examination revealed perfectly intact pieces of pancreas
without any sign of digestion. Based on this experience, the
present study was initiated. We speculated that the variabil-
ity in digestion efficiency between pancreata might be


















Isolaons aer switch 
to supplementary Ca2+ 
Figure 4. Cumulative sum chart test (CUSUM): cumulative plot of islet equivalent (IEQ) obtained after successive pancreas islet isolations
following the NNCIT protocol before and after the implementation of supplementary Ca2þ during the entire islet isolation process. The
dotted line indicates the switch. For every islet isolation, the difference from 200,000 IEQ is plotted. If the number of IEQ is above 200,000
IEQ, the next plot point is a positive addition to the graph; if below, a negative addition. The dotted line indicates the switch to
Ca2þsupplementation as part of the islet isolation process.
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– for example, that liberated from lysed adipocytes. This
notion is in agreement with the frequently reported benefi-
cial islet isolation outcomes obtained from pancreata with an
ischemic time of 2–4 h, as compared to those processed
immediately after procurement19.
In summary, additional supplementation of the media
used in clinical islet isolation with Ca2þ beyond the 5 mM
traditionally in stock solutions is required to achieve the
recommended [Ca2þ] of 5–7 mM to obtain optimal enzyme
efficiency. Ca2þ supplementation improves the digestion
efficacy and kinetics for consistent release of a high number
of intact and fully functional islets. Since no detrimental
effects on islet function or viability were observed, Ca2þ
supplementation, as described here, is now in standard use
at the islet isolation centers within the NNCIT, showing a
positive trend in islet isolation outcome (Figure 4).
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